Howard C Herrmann's profile photo

Howard C Herrmann

Featured in: Favicon wiley.com Favicon thelancet.com Favicon healio.com Favicon jwatch.org Favicon pcronline.com Favicon onlinelibrary.wiley.com

Articles

  • A Novel Device for Coronary Microvascular Dysfunction and Refractory Angina

    Jan 21, 2025 | jwatch.org | Howard C Herrmann

    Howard C. Herrmann, MD, reviewing The coronary sinus reducer, approved in Europe, appears to improve angina and quality of life in patients with CMD or refractory angina. Coronary microvascular dysfunction (CMD), characterized by abnormal vasodilatory capacity or intense vasoconstriction affecting smaller coronary arteries, can occur without epicardial obstructive coronary artery disease (CAD) and is a challenging condition without widely effective treatments.

  • A Randomized Trial of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation

    Dec 6, 2024 | jwatch.org | Howard C Herrmann

    Howard C. Herrmann, MD, reviewing Although major cardiovascular events were not reduced at 1 year, this study confirms a benefit in patient-reported outcome measures. Several recent trials demonstrate that transcatheter valve repair (TRILUMINATE; NEJM JW Cardiol Mar 6 2023 and N Engl J Med 2023; 388:1833) or replacement (TRISCEND II; NEJM JW Cardiol Nov 13 2024 and 2024 Oct 30; [e-pub]) can improve quality of life for patients with severe tricuspid regurgitation (TR).

  • Transcatheter Valve Replacement for Severe Tricuspid Regurgitation

    Nov 13, 2024 | jwatch.org | Howard C Herrmann

    Howard C. Herrmann, MD, reviewing Valve replacement improved symptoms and quality of life more than medical therapy. In this international, manufacturer-funded, randomized (2:1) trial ( NCT04482062), investigators compared transcatheter tricuspid valve replacement (TTVR) with medical therapy in 400 patients with symptomatic severe tricuspid regurgitation (TR; mean age, 79 years; 76% women).

  • Aortic-Valve Replacement vs. Clinical Surveillance for Asymptomatic Severe Aortic Stenosis

    Nov 7, 2024 | jwatch.org | Howard C Herrmann

    Howard C. Herrmann, MD, reviewing A strategy of early AVR was superior to clinical surveillance due to a reduction in hospitalizations. Although aortic-valve replacement (AVR) is recommended for severe, symptomatic aortic stenosis (AS), close clinical surveillance has been the standard of care for asymptomatic patients for more than 50 years. Two recent trials provide new data that challenge this recommendation.

  • New Data on Transcatheter Mitral Valve Repair

    Sep 3, 2024 | jwatch.org | Howard C Herrmann

    Howard C. Herrmann, MD, reviewing Transcatheter repair was associated with less heart failure hospitalization than medical therapy alone in one randomized trial - and was noninferior to surgery in another trial.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →